SCHEMBL3670195

SCHEMBL3670195

CCCCn1c(O)nc2ncc(Cl)cc21

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.40
ALDH1A1 P00352 2/20 0.40
MEN1 O00255 1/20 0.40
GAA P10253 1/20 0.40
KMT2A Q03164 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
TP53 P04637 1/20 0.37
MAPT P10636 1/20 0.37
HRH4 Q9H3N8 9/20 0.36
HPGD P15428 1/20 0.36
HTT P42858 1/20 0.36
HSD17B10 Q99714 1/20 0.36
HRH3 Q9Y5N1 3/20 0.35
HTR3A P46098 1/20 0.35
IRAK4 Q9NWZ3 1/20 0.34
LMNA P02545 1/20 0.34
HSP90B1 P14625 1/20 0.34
CHEK1 O14757 1/20 0.34
WEE1 P30291 1/20 0.34
RXFP1 Q9HBX9 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3666329 0.96 TLR8 (0.37) KDM4EALDH1A1MEN1GAAKMT2A
SCHEMBL3667095 0.94 PSEN1 (0.39) KDM4EALDH1A1MEN1GAAKMT2A
SCHEMBL3668071 0.93 HPGD (0.38) KDM4EHRH4HPGDHTTHSD17B10
SCHEMBL3671987 0.87 NUDT1 (0.45) KMT2AMAPTHRH4HPGDHTT
SCHEMBL3673651 0.85 APOBEC3G (0.38) KDM4EALDH1A1TP53MAPTHRH4
SCHEMBL3672462 0.85 HRH4 (0.36) MAPTHRH4HPGDHTTHSD17B10
SCHEMBL3675495 0.85 HRH4 (0.41) HRH4HRH3HTR3ACHEK1WEE1
SCHEMBL3669424 0.84 PLAU (0.37) GAAKMT2ASMN1; SMN2TP53MAPT
SCHEMBL3675941 0.84 KMT2A (0.42) KMT2AHRH4HPGDHTTHSD17B10
SCHEMBL3669322 0.82 HSP90B1 (0.37) HRH4HPGDHTTHSD17B10HRH3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7851484-B2 Certain chemical entities, compositions, and methods CYTOKINETICS, INC. (US) 2010-12-14 US claimed
EP-2139478-A1 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS Cytokinetics, Incorporated (US) 2010-01-06 EP claimed
WO-2008121333-A1 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS CYTOKINETICS, INCORPORATED (US) 2008-10-09 WO claimed
US-20080242695-A1 Certain Chemical Entities, Compositions, and Methods CYTOKINETICS, INC. 2008-10-02 US claimed
US-7851484-B2 Certain chemical entities, compositions, and methods CYTOKINETICS, INC. (US) 2010-12-14 US disclosed
EP-2139478-A1 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS Cytokinetics, Incorporated (US) 2010-01-06 EP disclosed
WO-2008121333-A1 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS CYTOKINETICS, INCORPORATED (US) 2008-10-09 WO disclosed
US-20080242695-A1 Certain Chemical Entities, Compositions, and Methods CYTOKINETICS, INC. 2008-10-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080242695-A1 Certain Chemical Entities, Compositions, and Methods TNNC1, TNNI3, TNNT2 KDM4E 4360/4885ALDH1A1 4750/4885MEN1 3647/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.